The World Bank has announced a new blue economy program that will catalyze funding and provide an operational response to the development challenges of the coastal-marine areas of the African continent.
The Blue Economy for a Resilient Africa (BE4RAP) program was announced at a World Bank COP 27 event, attended by Egypt’s Minister of Environment Yasmine Fouad, Tanzania’s Deputy Minister of Union and Environment Hamza Khamis Hamza and Morocco’s Deputy Budget Director for the Ministry of Economy. and Finance Youssef Farhat. The program aims to address the challenge faced by coastal countries to manage their coastal and marine resources to stimulate economic growth and reduce poverty, while adapting to the effects of climate change.
A first for the World Bank in Africa, a “Mangrove Blue Carbon Pilot Program” was announced as part of BE4RAP. The $13.5 million program includes financing of $2 million from IDA and $3 million from PROBLUE, a multi-donor trust fund hosted by the World Bank, and $8.5 million from the Danish energy company Ørsted. The funds will go towards the planting, technical assistance and maintenance for 20 years of 3,000 hectares of mangroves in Ghana, as part of the West Africa Coastal Areas Management (WACA) Program financed by the World Bank. Other donors, including private, public and multilateral partners, have expressed interest in contributing to a portfolio of blue economy investments in Africa.
“BE4RAP is about doing more, better and faster,” said Global Director for Environment, Natural Resources and Blue Economy of the World Bank Valerie Hickey. “Capitalizing on existing programs and partnerships, we rally under the leadership of coastal African countries and support each with financial and technical assistance.
A series of 12 thematic papers on BE4RAP solutions have been launched, showcasing the impact of existing World Bank programs and financing opportunities that can be scaled up for Africa to unlock the full potential of a resilient economy. From biodiversity-rich ecosystems to fisheries management and innovation, coastal countries in Africa can maximize the benefits of sustainably managed oceans. The program will build on successful programmatic experiences on the continent such as Morocco’s blue economy program, the Red Sea and the Gulf of Aden and analytical work such as the Blue Skies, Blue Seas report.
The Blue Economy for a Resilient Africa program is expected to convene a “Focus on Africa Blue Marketplace” in 2023. Building on the World Bank’s extensive existing portfolio in North Africa and Sub-Saharan Africa, the BE4RAP aims to mobilize new support , financing and partnerships to meet the ambition of COP 27 to have an Africa-wide initiative providing innovative climate solutions, in particular to blue economy.
Quotes from partners who have expressed their support for the program:
“The French Development Agency (AFD) is deeply concerned about the well-being of African peoples, cultures, countries and the environment. With a large portfolio of activities in all sectors on the continent, AFD is increasingly committed to climate, biodiversity and the SDGs. Addressing several of these challenges at once, the blue economy is a major part of the solution, and we want to fully partner with the World Bank on the BE4RAP. said Cassilde Brenière, Deputy Director of Operations, French Development Agency.
“We are very pleased that NDF funding to the World Bank for the West Africa Coastal Zone Management Program Scaling-Up Platform has supported the design of the innovative new blue carbon project for Ghana. It has unlocked funding from both the public and Nordic private sectors that has the potential to be replicated across the coastal landscape and in other countries in Africa. We look forward to further engaging with the World Bank and many other partners to promote a sustainable and resilient blue economy, including through initiatives such as the BE4RAP,” said Martina Jägerhorn, Program Manager, Nordic Development Fund.
“We see an untapped realization of the potential of using blue carbon in coastal and marine ecosystems for carbon sequestration. In our view, access to carbon finance should be simplified. Too often we see one or more intermediaries in carbon trading, leaving less carbon price available to recipient countries and people living in affected ecosystems,” said Ingrid Reumert, Group Stakeholder Relations Manager, Ørsted, Denmark.
“Local-level initiatives as derivatives of green civil society are one of the most important pillars for enhancing more resilient ecosystems. They are also a catalyst for strong solutions to many climate-related issues. I hope BE4RAP will be inclusive and provide a platform where communities and civil society can speak oute,” said Ahmed Yassin, co-founder, Banlastic, Egypt
Similarly, research organizations such as the National Research Institute for Sustainable Development (IRD) wish to commit:
“The IRD recognizes the importance of science and higher education for the blue economy and the climate in Africa. The IRD welcomed the collaboration with the World Bank on the African Center of Excellence for Coastal Resilience (ACECoR) organized by the University of Cape Coast, Ghana. Therefore, the IRD wishes to partner with BE4RAP and looks forward to developing partnerships that can support African countries, their institutions and their populations”, said Corinne Brunon-Meunier, deputy director of the National Research Institute for Sustainable Development (IRD).
Related
]]>The executive of an electric vehicle (EV) company says the requirement for EV shifters is costly.
While Singaporeans are ready to switch from gasoline-powered cars to electric vehicles (EVs), there are still factors holding them back. More than half of Lion City motorists plan to move away from fossil fuel vehicles and use EV instead in the future, a 2022 Epson study showed. Government data also revealed that new electric car registrations, even more than doubled in 2021.
Despite this will, Cecilia Ku, manufacturing company, managing director of Delta Electronics, said these numbers for adoption of electric vehicles in Singapore are “still very low”. Epson’s Climate Reality Barometer reported less than 20% shifted to electric vehicles.
Ku said one of the hurdles slowing the shift to electric vehicles is the expensive Certificate of Eligibility (COE) for such vehicles, which grants an individual the right to own and drive a vehicle in Singapore. According to ride-sharing company Grab, the COE “even costs more than the car itself.”
“I hope the government can look into the WCC as well. It’s because everyone is talking about how COE is still very expensive,” Ku said. Singapore Business Review on the sidelines of the Industrial Transformation ASIA-PACIFIC 2022 organized at the Singapore Expo.
Consulting firm KPMG also expressed the same sentiments, saying the the government has more space to introduce policies for EV users amid high car ownership costs due to taxes and COE.
Government subsidies to accelerate EV adoption are Singapore’s EV Early Adoption Incentive (EEAI) and Vehicular Emissions Scheme (VES), which can help consumers save up to $45,000 on the cost of purchase of a new EV.
October 2022 data from the Automobile Association of Singapore showed that the COE for electric vehicles up to 110 kilowatts (KW) costs $81,089, while the COE for electric vehicles over 110 KW is worth $110. $000.
Build more EV infrastructure
To speed up EV registrations in Singapore, KPMG has encouraged more infrastructure, which can solve the range anxiety of EV drivers. Range anxiety refers to the fear that an electric vehicle will not be charged enough on the road.
“I hope with the infrastructure built in Singapore, it can bring more convenience, so that drivers will switch from diesel car to the car you share with us in the future,” Ku said.
Among Delta’s EV solutions are energy storage systems and the Delta Green platform, shared by Ku.
She said these platforms will increase the energy demand of electric vehicle loads and monitor the energy intake and consumption by the electric car.
“I think it’s a way for Delta to already help the government and operators in Singapore overcome the limitations posed by infrastructure,” Ku said.
Delta also introduced EV chargers, including the AC charger, which has an output power of 7 to 22KW. AC charger refers to trickle charging, which is for commercial and household charging.
AC chargers can be used in single-family homes, apartments, and multi-unit workspaces. It can charge an electric vehicle for four to eight hours.
Referred to as a “fast charger”, the DC charger has an output power ranging from 25KW to 200KW. It can optimize the operating costs of public and commercial charging services, especially in sites with limited space.
DC chargers can be installed for retail and hospitality sites, commercial workplaces and fleets. It can charge from one to four hours.
DC High Power chargers can be installed in car parks, gas stations and intercity charging networks. It can charge an EV for 10-30 minutes.
]]>Newark, Nov. 16, 2022 (GLOBE NEWSWIRE) — The Brainy Insights estimates that the animal health market of $35.42 billion in 2022 will grow to $60.31 billion by 2030. The increasing pace of climate change is seen worldwide with increasing example of extreme weather changes like flash floods, frequent storms and heat waves. The increase in global average temperature is having a profound impact on animals, given their increased vulnerability to extreme climate change events. The slow process of evolution means that the majority of animals do not adapt to new changes and die because of these changes. Habitat loss and the re-emergence of pathogens leading to an increased risk of zoonotic diseases put animals at high risk of dying. Climate change affecting animals will have a direct impact on the global food industry. The serious consequences of not prioritizing animal health by developing life-saving vaccines and drugs to protect them will create a global food crisis. The imbalance caused by rising temperatures will alter land use patterns and affect food crops. Therefore, it is essential to address animal health with increased urgency.
Get a sample PDF brochure: https://www.thebrainyinsights.com/enquiry/sample-request/13019
Key overview of the animal health market
Asia-Pacific is expected to experience the fastest growth over the forecast period.
Asia-Pacific is expected to experience the fastest growth over the forecast period. The region’s extensive ranching is a vital source of revenue for the government; it is therefore crucial to focus on improving the animal health infrastructure. The market will witness high growth in the forecasted years owing to the growing focus on improving animal husbandry and husbandry to provide access to high quality food, medicine and feedstuffs. quality. The sophisticated and large pharmaceutical industries of China and India represent a distinct advantage for the animal health sector.
The production animal segment will grow the animal health market over the forecast period.
The Animal Types segment is divided into Production Animals and Companion Animals. The food producing animal segment led the market with a revenue share of around 57% in 2022.
The pharmaceuticals segment is expected to grow the animal health market over the forecast period.
The product type segment is divided into vaccines, medical food additives, equipment and disposables, pharmaceuticals, diagnostics and others. The pharmaceutical segment dominated the market with a market share of around 38% in 2022.
The market size of veterinary hospitals and clinics segment of USD 20.54 billion in 2022
The end-user segment is divided into reference laboratories, veterinary hospitals and clinics, point-of-care testing and others. The veterinary hospitals and clinics segment dominated the market with a market share of around 58% in 2022.
The retail segment market size of USD 17 billion in 2022
The distribution channel is divided into veterinary hospitals and clinics, retail, e-commerce and others. The retail segment dominated the market with a market share of around 48% in 2022.
For more insight on the analysis of this report, contact the research analyst: https://www.thebrainyinsights.com/report/animal-health-market-13019
Scope of Animal Health Market:
| Report cover | Details |
| Page number | 236 |
| base year | 2021 |
| Forecast period | 2022-2030 |
| Growth momentum and CAGR | Accelerate at a CAGR of 6.88% |
| Market Growth 2022-2030 | $60.31 billion |
| Market structure | Fragmented |
| Regional analysis | APAC, Europe, North America, South America and MEA |
| Successful market contribution | The North American region has emerged as the largest market for the global animal health market, with a market share of 33.91% in 2022. |
| Competitive landscape | Leading companies, competitive strategies, scope of consumer engagement |
| Profiled companies | Boehringer Ingelheim International GmbH, Covetrus, Elanco, Heska Corporation, Intervet International BV, Merck Animal Health, Novartis AG, Vetoquinol SA, Virbac, Zoetis |
| Market dynamics | Parent Market Analysis, Market Growth Drivers and Barriers, Fast and Slow Growing Segment Analysis, COVID 19 Impact and Future Consumer Dynamics, Market Condition Analysis for the Forecast Period. |
| Customization overview | If our report does not include the data you are looking for, you can contact our analysts and customize the segments. |
Market advancement
Merck Animal Health acquired Sense Poultry Ltd. in February 2021 to expand its vertical poultry business and gain access to environmental and health monitoring technology.
Market dynamics
Driver: the growing cases of zoonotic diseases
Animal habits have been destroyed due to climate change. Recently, the likelihood of catching zoonotic diseases from an animal vector, such as domesticated or exotic animals, has increased. For example, the covid-19 epidemic has killed millions of people around the world by infecting people with a vector of animal origin, most likely a bat. Attention to animal health has also increased due to many cases of slaughtering chickens to eradicate chicken pox or ducks to stop disease transmission to humans. Scientists have been motivated to create better vaccines, drugs, animal feeds, and feedstuffs as the possibility of zoonotic diseases spreading from animals to humans has increased.
Constraint: insufficient infrastructure
In low- and middle-income countries, implementation of government initiatives to improve animal health has been less than adequate. For example, recent events in India where hundreds of cattle died from lumpy skin disease show that there are not always preventive measures. Similar cases of killing chickens and ducks have resulted in significant national financial losses. A lack of adequate infrastructure will hamper the development of vaccinations, zoonotic disease surveillance, testing, tracing, isolation and treatment.
Opportunities: increased research and development spending
Government institutions have increased their spending to improve animal health due to the huge losses suffered at individual and national levels due to zoonotic diseases that lead to the death of animals. Growing government spending to develop better drugs, vaccines, tools and diagnostics to prevent and treat animal diseases will provide lucrative future prospects.
Challenge: Comprehensive and holistic drug approval process
Since animals are an important part of the food chain, damage to their health has a cascading effect on public health. Medicines and vaccines created to improve animal health must therefore undergo testing before being authorized for sale. Strict government regulations will hamper market development in developed countries overseeing the approval and use of pharmaceuticals, vaccines and other animal medicines.
Interested in getting the data? Inquire here at: https://www.thebrainyinsights.com/enquiry/buying-inquiry/13019
Some of the major players operating in the animal health market are:
• Boehringer Ingelheim International GmbH
• Covertrus
• Elanco
• Heska Company
• Intervet International BV
• Merck Animal Health
• Novartis AG
• Vétoquinol SA
• Virbac
• Zoetis
Coverage of key segments in the market:
By animal type
• Production animals
• Pets
By product type
• Vaccines
• Medical food additives
• Equipment and consumables
• Pharmaceutical products
• Diagnostic
• Others
Per end user
• Reference laboratories
• Hospitals and veterinary clinics
• Point-of-care testing
• Others
By distribution channel
• Hospitals and veterinary clinics
• Detail
• E-commerce
• Others
By region
• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, rest of APAC)
• South America (Brazil and rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)
Buy a single-user copy of the report directly: https://www.thebrainyinsights.com/buy-now/13019/single
About the report:
The market is analyzed on the basis of value (USD billion). All segments have been analyzed at global, regional and country level. The study includes analysis of more than 30 countries for each part. The report analyzes the drivers, opportunities, restraints and challenges to gain a critical overview of the market. The study includes Porter’s five forces model, attractiveness analysis, product analysis, supply and demand analysis, competitor position grid analysis, analysis of distribution and marketing channels.
About The Brainy Insights:
The Brainy Insights is a market research company, aiming to provide businesses with actionable insights through data analytics to improve their business acumen. We have a robust forecasting and estimating model to meet customers’ high-quality production goals in a short period of time. We provide custom (customer specific) and syndicated reports. Our union reporting repository is diverse across all domain categories and subcategories. Our customized solutions are designed to meet customer requirements, whether they are looking to expand or planning to launch a new product in the global market.
Contact us
Avinash D
Business Development Manager
Phone: +1-315-215-1633
Email: [email protected]
Web: http://www.thebrainyinsights.com
]]>
Hyundai Motor Co. (including Kia and Genesis) will soon be America’s best-selling electric vehicle maker, behind Tesla. This week’s Ioniq5 compact crossover clearly demonstrates why.
Slightly lower, slightly wider and on a longer wheelbase than the company’s best-selling Tucson, the Ioniq5 is a smash hit for Hyundai because it’s quiet, rides and drives great, and comes packed with the features and content that buyers now crave. And oh yes, it doesn’t burn gasoline.
Visually, the Ioniq makes a distinct statement. It is elegant, but masculine. It’s bold, yet refined. It’s smart, but affordable. Lever-style door handles raise to greet you, then retract mid-ride or when locked. The Access is like a compact crossover – easy to slide in or out.
The chassis is basically the lithium-ion battery – hence the longer 118-inch wheelbase, which improves handling and ride. The suspension is fully independent on each corner, while our dual-motor AWD Limited uses a 74kW electric motor up front and a 165kW motor in the rear. Total power is equal to 320 hp – enough power to create a giant backstroke when you exercise the throttle connected to the single-speed gearbox. With essentially one-pedal operation – there’s little freewheeling – the Hyundai requires some reorientation from the driver. However, you leap forward with enthusiasm – with acceleration that matches my Mustang GT.
The cabin feels austere at first – everything works, until you explore your eco-friendly materials and the various functions on the large dual control displays. Then it’s obvious that the Ioniq5 is a very modern car packed with technology and none of the idiosyncrasies of previous alternative vehicle experiences. I’m looking at you, Prius.
Try the programmable augmented reality head-up display, semi-autonomous driving modes (called Highway Driver Assist 2) or park assist — not even in the Ioniq5. The “shifter” is a rotating knob on a steering column rod. Of course, there’s SmartCruise, navigation, all-new mobile phone functionality, heated and air-conditioned seats with memory, plus a massive sunroof and power tailgate. Space is ample, front and rear, making this EV all the size most drivers will need. Include the optional HTRAC AWD, rear wheel drive is standard and the Ioniq5 is also ready for all seasons. It can even tow up to 2,300 pounds.
Other than a front trunk – the frunk – that was once where your engine was, the Hyundai’s compartment is still a functionally full bay with barely room for a large lunch. It was the only disappointment in a car that impresses every time you use it. Even the jaded petrol enthusiasts at Car & Driver chose the Ioniq5 as the electric vehicle of the year.
Now the numbers.
Pricing starts at $41,245 for rear-drive single-motor models with 168 hp and 220 miles of electric range. A mid-level rear-drive model with a 225hp long-range battery can go up to 303 miles for less than $50,000. Our top Limited model, with 320 hp twin engine and all-wheel drive, is rated up to 266 miles for $56,320 which includes $595 for Atlas White paint and floor mats.
Hyundai uses 800-volt batteries which are among the fastest EV batteries currently available for Level III charging – a 10% to 80% charging range takes just 18 minutes, with 350kW DC fast charging that rivals EVs costing three times as much.
The caveat: the severe shortage of fast-charging Level III chargers – anywhere. Most commercial or public space chargers are Level I units, which are pretty much irrelevant for a vehicle like the Ioniq5 – 15 hours of home charging on normal 110 current (which is Level I) added only 42 miles of range. If you’re doing 24 miles a day, like a round trip to Ellsworth, the Ioniq only uses 6% of its range.
After arriving home with the Ioniq5 on the first day, I had 20% range left, or about 52 miles. The on-board screen announced that it would be necessary 59 hours to achieve 100% charge on my current power supply. Highway range anxiety was simply unavoidable – a feeling that prolonged exposure and use would help erase. But the faster you go, the faster the range decreases, so you become very aware of your speed. Three separate displays inform you of your efficiency.
Level II charging, which is still rare in many parts of the country – and preferable for owners who travel long distances daily – would be the only necessity to recharge this sophisticated machine.
The Kia EV6 is comparable, while a larger Ioniq6 crossover will be available soon. A Genesis EV model arrives every day.
Game changer? Yes, the Ioniq5 will reshape the segment – and the number of us who travel. Is an EV for everyone? Not yet – there are far too many charging issues for the masses, on the proposed scale of use. Still, the Ioniq5 is an innovative statement, and that’s fine.
Next week: Ford Raptor 37
Tim Plouff reviewed the automobiles in the pages of The American Ellsworth weekly for almost two decades.
IFaced with a persistent rise in the prices of goods and services occasioned by runaway inflation in Nigeria, many civil servants earning around the minimum wage of 30,000 naira accept menial jobs to meet their basic needs.
A number of workers, who fall into this category, are now rationing basic necessities such as food, shelter and clothing to cope with the difficult economic situation prevailing in the country.
Being a public primary school teacher in the Kano metropolis on a monthly salary of 33,800 naira is not enough for AbdulHadi Bako to put food on the table for his family of seven.
Bako, 45, a level 7 officer, is fully aware of the enormous responsibilities that await him and assumes them headlong. After closing school around 2 p.m., he hits the road on a tricycle, commuting between neighborhoods to supplement his meager salary.
He said his salary of 33,800 naira was used to take care of groceries and a few errands that would last a month for his family, until recently when his purchasing power took the heavy toll of rising prices. inflation.
“Food prices keep rising and my salary is no longer enough to store food at home for a month,” Bako lamented, his voice filled with anguish. “Even though I only had a wife and child, there was no way to survive on 33,800 naira for a month.”
To bridge the huge gap between his salary and the cost of living, Bako gets behind the wheel every day at a time when he should be resting and preparing well for the next day’s task in class.
“I ride a tricycle after closing school to support the small salary I earn. In fact, I make more money doing it than teaching. This is how I was able to take care of myself and my family,” he said.
Although he is single, the 35,000 naira that Olamilekan Shorunke brings home every month is less than what he needs to live on and support his mother and two siblings. With the biting inflationary effect, which has depreciated the value of his salary sharply in recent times, Shorunke, a 29-year-old security guard on a Lagos State campus, is going the extra mile to fill the vacuum created by the derisory salary.
He said, “I am a bachelor. I have a fiancée, but what I currently earn does not encourage me to get married. When I was newly employed I was earning N20,000 before it was increased to N35,000 two years ago.
“I take care of my mother and my brothers and sisters. Every month I give him N10,000; give my siblings N5,000; buy groceries worth N10,000 and keep the remaining N5,000 for my transportation and other expenses.
“At this time last year, with 10,000 naira, I would buy a container of paint containing rice, beans, garri, 75cl of palm oil, peanut oil and a few other ingredients. But now I can only buy half of these items with N10,000. It’s really hard, but I’m trying to survive by the grace of God. From time to time, I do catering at parties to supplement my salary.
More than four months after raising funds through periodic contributions to rent a one-bedroom apartment in the Bariga neighborhood of Lagos, rent continues to burn as he struggles to find ways to furnish the apartment.
“I still live with my mother because I can’t afford to buy the necessary things to furnish the rented apartment,” he laments.
Bako and Shorunke’s struggles illustrate the struggle of millions of employed but poor Nigerians living on the 30,000 naira minimum wage in the face of runaway inflation.
Nigeria’s Consumer Price Index (CPI), which measures the average change over time in the prices of goods and services consumed daily by people, reached 20.77% in September 2022, from 20.52% in august. Current inflation rates are the highest since 2005, according to the National Bureau of Statistics.
The August increase was 3.52 percentage points higher than the rate recorded in August 2021 and a marginal reduction of 0.05% from the July 2022 rate.
The BNS attributed the increase to higher prices for bread and cereals, potatoes, yams and other tubers; fish, meat, oil and fat, which Bako, Shorunke and other Nigerians consume daily.
He also blamed the increase on “disrupted food supplies, increased import costs due to continued currency depreciation and a general increase in production costs”.
Addressing members of the Nigeria Labor Congress (NLC) at a public presentation in Abuja last month, Labor and Employment Minister Chris Ngige said the government plans to increase the current minimum wage of 30,000 naira.
Ngige said the increase in the minimum wage was necessary due to the current global inflation which has impacted people’s purchasing power.
However, many analysts described the move as impractical given declining government revenue and growing debt, which stood at 42.84 trillion naira as of June 30 and gobbles up 90% of all government revenue. in the service. Moreover, since President Muhammadu Buhari signed into law the minimum wage law in 2019, many states – according to union leaders – have failed to meet the payment of 30,000 naira, thus casting doubt on the implementation. of Ngige’s engagement at the national level.
Ngozi Obafemi, professor of economics at the University of Calabar, urged the government to raise wages and put in place policies to reduce the rate of inflation, noting that the latter would have far-reaching impacts on well-being. to be of the people.
Obafemi, a fellow of the African Economic Research Consortium and the Nigerian Economic Society, said overreliance on imported goods is aggravating inflation in Nigeria and advised that as the upcoming general elections approach , the incumbent government as well as the incoming administration should come up with initiatives that will make Nigeria a productive nation.
She said, “Nigeria is a consumer economy. We consume more than we produce. We cannot continue to consume without producing and expect incomes to rise or inflation to fall. The government must do something to increase production, especially exports. The government must also stop the theft of oil as this is the main reason why revenues have been cut.
“Many businesses have left Nigeria due to poor infrastructure and electricity, among other things. So the government must do something to encourage production. He must stop the import of fuel by repairing our refineries or building new ones. The high cost of fuel increases the cost of production as companies power generators at a high cost.
“The government needs to put infrastructure in place; taxes must be reduced to encourage people to produce so that our products are more than our consumption. If our production increases, it will certainly lower inflation. There is imported inflation; if we produce more at less cost, it will stop. For production to increase, policies that will reduce production costs must be put in place.
Obafemi’s observation echoes the NBS report on Nigeria’s 1.94 trillion naira foreign trade deficit in 2021, implying a negative trade balance as the country’s economy remains import-driven .
In 2020, Nigeria recorded its first annual trade deficit in four years when imports exceeded exports by 7.37 trillion naira.
In its report, “Foreign Trade in Goods Statistics (Q4 2021)”, released in March 2022, the BES revealed that the country’s total exports for 2021 stood at N18.91 trillion while total imports were assessed at N20.84 billion.
“The value of total imports in 2021 stood at N20.84 trillion, 64.11% higher than the value recorded in 2020, while total exports were valued at N18.91 trillion, a increase of 50.99% compared to the recorded value. in 2020. Overall in 2021, merchandise trade recorded a deficit of N1.94 trillion,” the report states.
An economist from Olabisi Onabanjo University, Ogun State, Prof. Sheriffdeen Tella, said that to tackle headline inflation, government needs to design and implement policies that will boost local production and strengthen the naira against the dollar.
“The government said they were considering raising wages, but I know they are saying this to prevent the union from complaining. What the government should be doing is making sure that inflation goes down; ensure the naira appreciates and production improves. Once production improves, some of those prices will come down,” he said, saying Nigeria is largely a consumer country.
Tella added, “Once we are able to put policies in place to improve production at lower cost, prices will generally come down. When you say that you are going to increase wages, there is what is called an “announcement effect” which will cause prices to rise. People who don’t work for the government will also want to have their own cut. But if we improve production, there will definitely be enough for people to buy and prices won’t go up anyway.
“The government also needs to strengthen the exchange rate. When the exchange rate improves, those who want to import raw materials will pay less. And that will help bring down the prices of the goods they produce. We must also encourage farmers to produce. Insecurity chased them away. The government must improve security.
]]>Without European special order, performance, and classic cars, should be at the top of every gearhead’s wish list. Make them affordable too, and you can’t go wrong.
The good news is that there are hundreds to choose from. With fast sedans, coupes and many sports cars, the choice is vast and grows from year to year. We’re not just talking about mainstream stuff either. The obvious choice would be a Lotus Elise S1. But, with a little extra effort, you can find more rewarding Lotus cars worthy of your time and money.
Likewise, why settle for a BMW M-sport car when you could have an Alpina? The now in-house tuner has dozens of classics in a back catalog that are faster and rarer.
It’s about having your cake and eating it. Whatever badge you fancy, there’s a classic car on a budget. And it’s guaranteed to put a smile on your face.
10/10 Ferrari 400i
Every dog has its day, so the unloved Ferrari 400i is gaining popularity. Even so, it won’t win any beauty awards, but there’s still plenty to love. All the important ingredients are there. A Pininfarina-style front-mounted V12 engine, and of course the Prancing Horse badge.
Still, it took gearheads a long time to see the merits of the Ferrari 400’s sporting credentials. Boasting a 306bhp front-rear-wheel-drive chassis, this Ferrari is quick when called upon, peaking at 149mph. Grab one while you can, prices are on the rise.
9/10 Alpine B11 3.5
Grab a capable BMW 7 Series, tweak the engine and stick on custom wheels and badges. Indeed, that’s all Alpina did, but the results tell a different story. Greater than the sum of its parts, the trump card of the B11 3.5 is its rarity with a seven-year production run totaling 332 cars.
Still powered by BMW’s M30B35 straight-six, tweaked to deliver 250bhp, up from the standard 7 Series’s 217bhp. The gains boost the top speed to 152mph while slashing the 0-60mph time by a few tenths. But, the exclusive is cheaper than its rarity would suggest, expect to pay $14,000 for a car from the late 80s.
8/10 Alpine A310 V6 GT
Taking eccentricity to another level, Alpines A310 is a classic that flies under the radar. Weird to have a rear mounted engine like a Porsche 911, but much less popular. Produced from 1971 to 1984, the A310 could be fitted with a choice of four- and six-cylinder engines.
By far, the V6 is the most capable with 190 hp, which translates to a top speed of 142 mph. Under the skin, the Alpine is similar in design to the DeLorean DMC-12. Only done better, cheaper and faster.
7/10 Bentley Turbo R
In terms of metal bang for your buck, the Bentley Turbo R represents unbeatable value for money at $20,000. The property comes with a few caveats. Not the least is the turbocharged engine’s thirst for gasoline, which can go down to single digits.
A turbocharged Bentley? In 1985, Bentley, aided by Garret-AiResearch, upgraded the 6.75-liter V8 engine with a T-04 turbo. As a result, power output jumped to 384 hp; almost double. Despite the big power gains, the Bentley is a beast of a car weighing 5400 pounds, hitting 60 mph in 6 seconds.
6/10 Lotus Excel SE
Fancy a Lotus bilge but don’t like the limitations of the Esprit’s cockpit? The Excel offers much of the same Chapman-era brilliance, with a few twists. Different by having a 2+2 cockpit makes the Excel more practical, although rear seat space is limited.
The biggest change is under the hood, the front one. The switch to a front-rear-wheel-drive chassis might have sports car fans racing for the hills. But Excel is just as capable and known for its 50/50 weight distribution and precise handling. True to Lotus form, Excel has undergone several changes over its lifetime. The later SE spec cars used a higher compression 912 type engine.
5/10 Volvo 850 T5-R
Swedes are diehard car junkies with a twisted sense of humor. Any gearhead turning on the TV to catch touring car action in the early 90s would be in for a shock. Volvo, the Swedish automaker famous for its tank-like constructions and safety, has gone racing.
Think a family wagon-based race car with a turbocharged engine, and you won’t be far off. Much of the credit belongs to TWR. Under the hood of this boxy wagon is a 2.4-liter turbocharged five-cylinder engine developing 247 hp. Despite their rarity, prices start at around $20,000.
4/10 TVR Tuscan V8
TVR does not do things by halves. Big engines and lightweight constructions have been the norm since 1946. The Tuscan’s first outing in 1967 used Ford Windsor V8s varying between 4.7 and 4.9 liters rated at 275 hp and up.
If it’s drama and performance you crave, the Tuscan delivers that and more. Weighing 1900 pounds, the Tuscan is a lightweight rocket that hits 60 mph in 5.1 seconds. Fast, light and reliable, prices start at $40,000.
3/10 Renault Sport Spider
The task of naming a Renault sports car is not a trick question. For a time in the 90s, Renault took on the Elise with the Sport Spider. Lotus won that one on driver dynamics. Both used a similar layout, an aluminum chassis and a mid-engine.
Renault’s ticket to the affordable sports car market has failed. More expensive to build, the gearheads soon realized how well the Spiders performed in the face of the price gap. However, Renault had a trick up its sleeve with a track version with a 2.0-liter engine developing 210 hp. Unfortunately, that wasn’t enough to save the car. The rarity has yet to inflate prices, expect to pay $28,000.
2/10 Jaguar E-Type S3 Coupe/Roadster
Dream ride or reality? Choose the right E-Type and you’ll save a lot of money. Jaguar needing a platform to launch its V12 engine tainted the E-Type’s reputation with the S3. A little more power and tons of extra weight didn’t sit well with buyers.
Classic collectors would be wise to seek out an XKE S3, which is cheaper to buy and still beautiful to look at. However, good deals follow one another. Swapping the sleek lines of Roadsters for the practicality of a 2+2 coupe can save you even more money. In a comparable comparison, there could be a difference between $30,000 and $46,000.
1/10 Porsche 928 GT
Porsche purists buy 911s for their bold handling. But if you want the most performance in a comfortable cruiser, the 928 GTS wins hands down. Almost all performance results in a top speed of 171 mph with sixty taking 5.1 seconds. The 928 is the neglected relative that everyone forgets.
Highway-smashing speed comes from a front-mounted 5.4-liter V8 making 350 hp. It was the Porsche that nearly killed the 911, and the car all gearheads should heed. Depending on the year, prices start at $35,000.
]]>- Four main trim levels, plus an exclusive, limited-run Launch Edition
- Gas models get 48-volt mild-hybrid assist
- On sale now from £31,880
After four years on the market, Mercedes has given the fourth generation A-Class a facelift. As before, the new Mercedes A-Class is available in hatchback and sedan bodies; However, it now features a revised exterior design, 48-volt mild-hybrid assist, as well as an update to the already impressive suite of in-car tech.
Top 10 best plug-in hybrids 2022
The new Mercedes A-Class is now on sale from £31,880 which, unlike most new cars, is actually slightly cheaper than the outgoing model. Despite the growing popularity of SUVs, the premium family sedan segment remains competitive, with the A-Class’ main rivals being the Audi A3, BMW 1 Series and DS 4.
2022 Mercedes A-Class: Pricing and Trim Levels
Buyers can specify the new Mercedes A-Class in one of five different trim levels: Sport Executive, AMG Line Executive, AMG Line Premium, AMG Line Premium Plus and the exclusive limited-run Launch Edition. Starting at £31,880, the entry-level Sport Executive comes standard with Mercedes’ MBUX infotainment system which includes two 10.25-inch screens mounted side-by-side. The other standard kit includes 17-inch alloy wheels, adaptive LED headlights, heated leatherette front seats, dual-zone climate control, wireless phone charger and rear-view camera.
Starting at £33,980, the AMG Line Executive adds a more racy body kit along with 18-inch alloys and a set of form-fitting sports seats. Next up is the £34,605 AMG Line Premium range which adds augmented reality navigation and illuminated skid plates. An extra £3,650 gets you the AMG Line Premium Plus range, which includes model-specific 19-inch alloy wheels plus a power driver’s seat, head-up display, 360-degree camera and panoramic sunroof .
Finally, the exclusive A-Class Launch Edition will only be available for a limited time and from £41,480. To distinguish itself from the regular versions of the A-Class, this one features 19-inch gloss black wheels and is only available with the A 200 powertrain.
Design and interior
The average passer-by may have trouble identifying the facelifted A-Class from the outgoing model as the visual updates are subtle. The new baby Merc gets revised LED headlight and taillight designs, along with a new hood with “power bulge” creases. High-end AMG-Line models see even more changes with a deeper front bumper and rear diffuser, plus a new grille, studded with miniature three-pointed stars – as seen on the latest Mercedes Class C.
As before, the Mercedes A-Class dashboard is dominated by a pair of 10.25-inch screens. These now run Mercedes’ latest iteration of its MBUX operating system and also come standard with wireless Apple Carplay and Android Auto. Drivers can create individual profiles via the in-display fingerprint reader, adjusting seat position, climate controls and the overall look of the screens to suit their preferences.
The new A-Class also includes Merc’s new multi-spoke steering wheel, which debuted on the facelifted Mercedes E-Class. This features touch controls allowing the driver to adjust settings on the infotainment screen without taking your hands off the wheel.
Engines and powertrains
Under the hood, the facelifted A-Class gets what is perhaps its biggest overhaul compared to the outgoing car. The A 180 and A 200 petrol engines now get support in the form of 48-volt mild-hybrid technology. This works in tandem with the car’s four-cylinder engine to improve fuel economy, while giving a temporary additional 14bhp boost in acceleration. Mercedes claims the A 180 should now be able to return to around 50mpg on the combined WLTP cycle, with the more powerful A 200 only slightly behind.
Mercedes has reduced the diesel range to a single model: the A 200 d. This hasn’t received any form of mild-hybrid tech, however, it’s still said to return around 48mpg on the combined WLTP test cycle.
Company car drivers will be pleased to hear that the A 250 e plug-in hybrid has been updated for 2023 and will go on sale towards the end of 2022. The electric motor has been tweaked to bring total output to 215hp – an increase of 7 hp. As before, Mercedes says the plug-in A-Class will be capable of around 44-50 miles on electric power alone, although in real-world driving it’s likely to be towards the lower end of that estimate. Charging speeds also go up to 11kW AC from 7.5kW; charging from 10-80% will now only take 25 minutes when connected to a public DC charger.
Unfortunately, the hot hatchback A 250 petrol was discontinued; those looking for even more power can opt for one of two high-performance AMG variants. Like the standard petrols, the A 35’s 2.0-liter four-cylinder engine also received 48-volt mild-hybrid assistance. This adds a temporary 14bhp boost to the car’s already impressive 302bhp. What’s more, the A 35 now features the same eight-speed dual-clutch as the top-end 415bhp A 45 S – however, this doesn’t get the mild-hybrid tech of its lesser siblings.
Are you looking for a luxurious but not too big car? Check out our list of the 10 best small luxury cars
]]>
The importance of AI in the pharmaceutical space has grown exponentially over the past few years, driven by global demand for a COVID vaccine at the height of the pandemic. Additionally, AI has proven useful throughout the pandemic, while offering a glimpse into the technology’s future promise.
According to a widely quoted 2021 Evaluation on the impact of AI applications in the wake of COVID-19 from the academic journal Frontiers in Medicinethese technologies have achieved “high performance in diagnosis, prognosis assessment, epidemic prediction and drug discovery for COVID-19”.
The report then concluded from their research that AI “has the potential to significantly improve the efficiency of the existing medical and healthcare system during the COVID-19 pandemic.”
In this article, we provide a brief overview of how AI has been used in the wake of the pandemic to:
- Accelerating drug discovery and production
- Streamline clinical reporting workflows
- Accelerate data validation
After a brief summary of the first two trends, we’ll take a closer look at a use case where Pfizer enlisted an AI vendor to help cleanse patient data to produce faster results for patients. clinical trials of their COVID-19 vaccine. Finally, we will conclude by taking a closer look at the frontiers of AI’s potential impact on clinical trial outcomes.
But first, let’s start our overview by taking a closer look at the impact of AI capabilities on the drug discovery process.
The future of drug discovery
The drug discovery process is extremely expensive and time-consuming. According to a report by PhRMA:
- The cycle from research to market takes at least ten years, with clinical trials taking an average of six to seven years.
- The average cost to develop an effective drug is $2.6 billion.
- The overall probability of clinical success (i.e. FDA approval) is estimated to be less than 12%.
The time spent in the research-to-market cycle for vaccines is specifically similaralthough less costly: up to $500 million, according to the International Vaccine Institute.
The pharmaceutical industry is under pressure to find new and better ways to manage the drug discovery process, and the answers are now more easily within reach. Big pharma – including Pfizer and Sanofi – use AI and machine learning to make this process faster and more cost effective.
In the case of Pfizer, the company managed to produce an FDA-approved vaccine in just under a year -; no small feat. According to a Pfizer Press release and substantiated by the media, AI and machine learning were used to accelerate the processing of a massive dataset to develop their PAXLOVID vaccine.
In a more recent case involving the development of an oral drug for COVID, Pfizer also claims to be using AI to help screen millions of potential compounds designed to affect molecular drug targets.
In the case of Sanofi, the pharmaceutical giant complaints on its website to use AI and machine learning to analyze anonymous data from around 450 million patients. The company recently published a press release revealing a partnership with Exscientia, an AI drug design and development company. The deal has a potential value of $5.2 billion.
Streamlined reporting process
Time is of the essence in the drug discovery process.
One of the most time-consuming parts of the drug discovery process is the preparation and generation of Clinical Study Reports (CSRs). According to a study Posted in Clinical researcherthe average time taken to complete the CSR is 109 days, or about 3.6 months.
This lengthy process not only uses company resources, but also prevents potentially useful drugs from advancing to potentially benefit patients.
Whatever the scenario, CSRs are essential; but much of the work is spent on repetitive tasks, requiring the valuable time of highly skilled healthcare professionals. AI can reduce the time taken by CSRs, freeing up the time of medical writers.
AI-enabled software tools can automate much of the CSR writing process. Time savings with CSR automation solutions vary by vendor. A company, ZYLiQ.ai, complaints to save medical writers 60-70% on time.
Another company, Narrativa, complaints a 65% reduction in time as well as an average cost reduction of 40% for CSR drafting.
Most user workflows of AI-based CSR solutions follow a similar pattern:
- Model selection and configuration (output)
- Download source documents
- System Generated CSR Review
- CSR User Edition
- Finalization and approval of release documents
Automating CSR content with AI helps simplify the review process by streamlining the generation of reliable, repeatable, and quality text. Among the range of current AI applications, natural language generation (NLG) is widely used in financial and medical writing for facilitate a consistent writing style throughout the document.
The CSR approach often requires information that is known only to a medical writer. Only a specific person may be able to explain the real value and meaning of the data.
In this case, the writer can program how the document will be read and how the facts fit together. NLP systems can be trained on the specific writing style and medical jargon required for a particular CSR.
A COVID Use Case: Accelerated Data Validation at Pfizer
After clinical trials, patient data needs to be “cleaned up” enough for scientists to accurately analyze the results. Moreover, the development of such a capacity would take a long time and could therefore further delay the process.
At the time, Pfizer was trying to get its vaccine approved for emergency use by the FDA and couldn’t afford any delays. The company decided to launch a competition to develop an AI-powered tool capable of quickly managing and cleaning clinical data.
A company called Saama Technologies won the competition with its Smart Data Query (SDQ) solution.
Saama states in his case study [pdf] report that the SDQ platform speeds up data cleansing and ensures data quality by automating the query management process. The report further states that Saama’s solution leverages the following AI capabilities:
- Machine learning to predict data deviations
- Natural language processing to help detect adverse event data and use medical history and case report forms for data consistency, and process over 750,000 free text sentences
Saama says the resulting AI-augmented workflow goes like this:
- Site investigators feed electronic case report forms (eCRFs) into their electronic data capture (EDC) system, integrated with Saama’s Smart Data Query (SDQ) platform.
- The SDQ platform reviews data and provides data managers with forecasts for their review.
- The EDC automatically generates queries in the form of eCRFs, sorted by confidence intervals and highlighting any data discrepancies.
- Managers then review each discrepancy and proposed response through the SDQ interface, assigning “open” requests to the eCRF already in the EDC or signing (step 6, shown in Figure 1 below). below) the correct changes.
- SDQ recognizes any already correct query text and uses this data to improve its algorithm. If the query text contains errors, reviewers can edit the response (step 7) before issuing a query. SDQ applies the data from these corrections to its algorithm.
The report features a helpful illustration illustrating the ease of the above workflow (Figure 1 below):
(Figure 1. Source: Saama Technologies [pdf])
According to the case study report, the result was that the AI reduced the median number of calendar days to generate queries from 25.4 days to 1.7 days across all vaccine studies.
Throughout the report, Samma also claims that their algorithms can help link potential treatments to precise biological causes in a much more efficient and rapid manner than the trial-and-error approach characterizing the traditional drug discovery process.
According to them, a lake of information can now be reduced to a small pool of relevant data in a significantly shortened time.
Looking Ahead: Accelerating Trial Outcomes
Another potential advantage of this new technology is that test results could be obtained much sooner. Driven by the Covid-19 outbreak, we are entering an era where algorithms can analyze clinical data and estimate simulated patient journeys through the trial, accurately predicting outcomes.
In a recent article for the famous academic journal Nature, it is reported that German biotech company Evotec was able to shorten the discovery process from 4-5 years to 8 months using AI.
By disrupting traditional testing methods with these capabilities, pharmaceutical companies can potentially reduce the average test cycle from years to hours. The AI platform, ‘Centaur Chemist’ of exscientiacan supposedly “sort and compare various properties of millions of potential small molecules… for 10 or 20 to synthesize, test and optimize”.
Further investment and development can transform these AI-based methodologies into increasingly robust and reliable simulation tools for data-only clinical trials. A outstanding example of the current trend exists in the “Immune System GPS” model recently unveiled by Pfizer.
]]>Singtel has announced the deployment of Singapore’s greenest radio cell, the Ericsson AIR 3268, on its 5G network.
This is part of Singtel’s ongoing sustainability and decarbonization measures to achieve net zero emissions by 2050 and paves the way for more such radio cells to be deployed across the country to increase its 5G coverage. national.
The AIR 3268 radio is expected to save up to 18% more power and weighs around 40% less than previous generations of 5G radios. At only 12 kg, its proportions simplify upgrades and facilitate the acquisition and installation of new sites on towers, roofs, poles and walls, even in difficult places. It also makes a 5G site 76% lighter than a 4G site that typically requires multiple radios, while providing the same network capacity. This further reduces the overall power consumption of Singtel’s 5G network, which is already up to 58% less than current 4G.
The AIR 3268 is designed to provide real-time channel estimation and ultra-accurate beamforming – or elimination of unwanted noise interference – to accelerate 5G midband spectrum deployment and increase capacity, coverage and connectivity speeds, improving mobile experiences for customers.
Ease of deployment and improved energy efficiency
Singtel 5G is a greener technology with higher data transfer rates than any previous generation of wireless technology, operating on a wide spectrum of 100 MHz that provides cellular capacity comparable to four Singtel 4G bands combined.
Deployment of AIR 3268, the industry’s lightest and smallest Massive MIMO (multiple-input multiple-output) is another step in Singtel’s power-saving improvements as it explores mobile technologies smart and durable that optimize the use of power and energy in its operations.
Anna Yip, Managing Director, Consumer Singapore, Singtel
We are constantly looking for ways to provide Singapore’s greenest 5G network while further reducing our carbon footprint. By integrating energy-efficient technologies into our operations and infrastructure, we aim to build a better and more sustainable future, while continuing to deliver the best network performance and user experience to consumers and businesses through our 5G solutions and services. With an optimized network, even end users will be able to save energy on their mobile devices, which will make them part of the movement of building a better future together.
Martin Wiktorin, Director of Ericsson Singapore and Philippines
Sustainability and energy efficiency are a priority for us at Ericsson. The deployment of our energy-efficient AIR 3268 radio as part of Singtel’s 5G network is an important milestone in our broader sustainability plan, which focuses on breaking the energy curve by enabling energy-saving software. energy, building 5G with precision and intelligently exploiting site infrastructure. This will help manage mobile traffic growth while reducing energy consumption.
Global Single-Use Products in Biopharmaceutical Market, By Product Type {(Work Equipment [Flask, Containers, Syringes, Pipettes tips, Centrifuge tubes, Hand Gloves, Face Mask, Filters, Tubes, Others]), by device (single-use bioreactor, isolators, membrane valves, canister, chromatography systems, filtration systems, mixing systems and others)}, by end user (pharmaceutical companies, biotechnology companies and research institutes) and by region (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) is estimated at US$1,821.2 million in 2021 and is expected to grow at a CAGR of 16.7% during the period forecast (2022-2028).
Request sample report (including full table of contents, table and figures) @
https://www.coherentmarketinsights.com/insight/request-sample/4903
The major players are involved in receiving drug approvals from regulatory authorities for single-use products, which is again expected to boost the growth of the global single-use products market in biopharmaceutical market during the forecast period. For example, on July 22, 2021, Becton, Dickinson and Company, a multinational medical technology company, received U.S. Food and Drug Administration (FDA) approval for vacutainer plus citrate plasma tubes, which are used for collection of blood to store, or transport or test for identification of coagulopathy and also for COVID-19 test.
The increasing research and development activities of the major players of single use products for pharmaceuticals are expected to drive the growth of the global market for single use products in the biopharmaceutical market. For example, on March 24, 2021, GEA Group, a pharmaceutical service provider, launched the single-use kytero separator, designed to harvest fermentation broths and cell cultures. This separator has the ability to increase maximum yield, gentle product handling and high separation efficiency, and helps reduce production time.
The coronavirus disease (COVID-19) pandemic is expected to drive the growth of the global disposables market in the biopharmaceuticals market during the forecast period owing to the increase in vaccine manufacturing. For example, on October 19, 2021, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) released data on the production of the COVID-19 vaccine, which indicates that globally, the production of the dose of COVID-19 will exceed 12 billion per year. 2021. And the production may double according to the requirements of the COVID-19 outbreak worldwide.
Growth in research and development activities for single-use products by market players is also expected to augment the growth of the global single-use products market in biopharmaceutical market. For example, in September 2018, Merck, a pharmaceutical company, published a case study on complete single-use ADC technology from development to scale-up, where the challenges of single-use antibody conjugate manufacturing -drugs (ADC) were mentioned, the study says. This production involved longer processing at a higher temperature than is typical for ADC manufacturing, placing the process at a higher than normal risk of bioburden growth.
Request a PDF brochure with the latest information @ https://www.coherentmarketinsights.com/insight/request-pdf/4903
The growing awareness program among market players is expected to boost the growth of the global single-use products in biopharmaceutical market, during the forecast period. For example, on October 6, 2021, Entegris, a U.S. provider of products and systems that purify, protect, and transport critical materials used in the manufacturing process of semiconductor devices, hosted the 10th Annual Merck Single-Use Virtual Conference. Manufacturing Symposium which includes participants from Merck’s global Single Use Network (SUN) community. The focus of this virtual conference was on COVID-19, Rapid Implementation and Scaling, Streamlining, Lifecycle Management and Supply Chain Robustness, Responsible Consumption, Security design and solving challenges with new single-use technologies are all topics covered at this year’s conference. on single-use technologies (SUT).
Key takeaways from the global single-use products in biopharmaceuticals market:
The global single-use biopharmaceuticals market is expected to grow at a CAGR of 16.7% over the forecast period (2021-2028), driven by growth in major markets, particularly in Europe. Additionally, the North America region accounted for a major market share in 2020.
Growing involvement of regulatory authorities for advanced products by market players and research institutes is expected to drive the growth of the global single-use biopharmaceuticals market over the forecast period. For example, on November 22, 2021, the United States Food and Drug Administration (FDA) released the Medical Countermeasures Initiative (MCMi) for advanced manufacturing, where the requirement for an innovative product is needed. . The USFDA mentioned facilities such as large-scale manufacturing, accelerating therapy. development, shorten processing steps and increase product manufacturing.
Some of the major players involved in the global biopharmaceutical disposables market include Aber Instruments, Adolf Kühner AG, Thermo Fisher Scientific, Bio-equip, Pall corp., C-Cit Sensors AG, Corning Life Sciences, Eppendorf , GE Healthcare, Gemu GmbH, Merck, Avantor, Meissner, New Horizon Biotech, PBS-Biotech, Xcellerex and Single Use Support GmbH.
Reasons to Buy this Disposable Products in Biopharmaceuticals Market Report
It attempts an analysis of the concurrent scenario.
Current and exceptional product revenue market.
In-depth data on regional survey and competitive landscape structure.
It benefits from creating awareness of important key product segments.
Marketing strategies, opportunities and development factors are explained.
Estimation of the market size of Single-Use Products in Biopharmaceuticals and recent advancements in the industry are explained.
Buy this full activity report @
https://www.coherentmarketinsights.com/insight/buy-now/4903
Contents
Chapter 1 Industry overview
1.1 Definition
1.2 Assumptions
1.3 Scope of research
1.4 Market Analysis by Regions
1.5 Biopharmaceuticals Disposable Products Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Impact on Biopharmaceutical Disposable Products Industry
Chapter 2 Global Single-Use Products Competition in Biopharmaceuticals by Types, Applications, and Top Regions & Countries
2.1 Global Single-Use Products in Biopharmaceuticals (Volume and Value) by Type
2.3 Global Single-Use Products in Biopharmaceuticals (Volume and Value) by Regions
chapter 3 Generation market analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Single-Use Products in Biopharmaceuticals Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Market analysis of single-use products in biopharmaceuticals in North America
Chapter 6 East Asia Disposable Products Market Analysis in Biopharmaceuticals
Chapter 7 Market analysis of single-use products in Europe in biopharmaceuticals
Chapter 8 South Asia Disposable Products Market Analysis in Biopharmaceuticals
Chapter 9 Southeast Asia Disposable Products Market Analysis in Biopharmaceuticals
Chapter 10 Analysis of the Middle East Disposable Products Market in Biopharmaceuticals
Chapter 11 Market analysis of single use products in Africa in biopharmaceuticals
Chapter 12 Market Analysis of Single Use Products in Oceania in Biopharmaceuticals
Chapter 13 Analysis of the South America Disposable Products Market in Biopharmaceuticals
Chapter 14 Company profiles and key figures for single-use products in the biopharmaceutical sector
Chapter 15 Global Disposable Products in Biopharmaceuticals Market Forecast (2022-2028)
Chapter 16 conclusion
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.
Contact us:
Mr Shah
Consistent market information
1001 4th Ave, #3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837